Cover Image
市場調查報告書

全球再生醫療市場:各產品類型(細胞治療,基因治療,組織工程,小分子·生技藥品),各材料,各用途 - 全球機會分析與產業預測

Regenerative Medicine Market by Product Type, Material, and Application - Global Opportunity Analysis and Industry Forecast, 2017-2023

出版商 Allied Market Research 商品編碼 648114
出版日期 內容資訊 英文 235 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
全球再生醫療市場:各產品類型(細胞治療,基因治療,組織工程,小分子·生技藥品),各材料,各用途 - 全球機會分析與產業預測 Regenerative Medicine Market by Product Type, Material, and Application - Global Opportunity Analysis and Industry Forecast, 2017-2023
出版日期: 2018年05月01日 內容資訊: 英文 235 Pages
簡介

本報告提供全球再生醫療市場相關調查,彙整市場現狀與成長預測,各產品類型,各材料,各用途,各地區趨勢,及加入此市場的主要企業簡介等資料。

第1章 簡介

第2章 摘要整理

第3章 市場概要

  • 市場定義和範圍
  • 主要調查結果
  • 波特五力分析
  • 市場趨勢
    • 促進要素
    • 阻礙要素
    • 機會

第4章 各產品類型市場

  • 概要
  • 細胞治療
  • 基因治療
  • 組織工程
  • 小分子·生技藥品

第5章 各材料市場

  • 概要
  • 合成材料
  • 生物學的衍生材料
  • 基因改造材料
  • 醫藥品

第6章 各用途市場

  • 心血管
  • 腫瘤
  • 皮膚
  • 肌肉骨骼
  • 傷口護理
  • 眼科
  • 神經科
  • 其他

第7章 各地區市場

  • 概要
  • 北美
  • 歐洲
  • 亞太地區
  • 南美

第8章 企業簡介

  • Acelity Holdings, Inc.
  • Athersys, Inc.
  • Cryolife, Inc.
  • Integra Lifesciences Corporation
  • Isto Biologics
  • Medtronic Plc
  • Organogenesis Inc.
  • Stryker Corporatio
  • U.S. Stem Cell, Inc.
  • Zimmer Biomet Holdings, Inc.

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: LI_16391

The global regenerative medicine market was valued at $5,444 million in 2016, and is estimated to reach $39,325 million by 2023, registering a CAGR of 32.2% from 2017 to 2023. Regenerative medicines repair, replace, and regenerate tissues and organs affected due to injury, disease, or natural ageing process. These medicines help restore the functionality of cells & tissues and are applicable in numerous degenerative disorders such as dermatology, neurodegenerative diseases, cardiovascular, and orthopedic applications. Researchers focus on developing technologies based on biologics, genes, somatic as well as stem cells. Stem cells are capable of proliferation and differentiation and hence, are critical in this field.

The major factors that boost the market growth include technological advancements in tissue and organ regeneration, increase in prevalence of chronic diseases and trauma emergencies, prominent potential of nanotechnology, and emergence of stem cell technology. In addition, rise in degenerative diseases and shortage of organs for transplantation are expected to fuel the growth of the market. Moreover, utilization of nanomaterials in wound care, drug delivery, and immunomodulation has opened numerous growth avenues for the regenerative medicines market. However, stringent regulatory barriers and high cost of the treatment are likely to hinder the market growth.

The global regenerative medicine market is segmented based on product type, material, application, and geography. Based on product type, the market is classified into cell therapy, gene therapy, tissue engineering, and small molecule & biologic. Depending on material, it is categorized into synthetic material, biologically derived material, genetically engineered material, and pharmaceutical. Synthetic material is further divided into biodegradable synthetic polymer, scaffold, artificial vascular graft material, and hydrogel material. Biologically derived material is further bifurcated into collagen and xenogenic material. Genetically engineered material is further segmented into deoxyribonucleic acid, transfection vector, genetically manipulated cell, three-dimensional polymer technology, transgenic, fibroblast, neural stem cell, and gene-activated matrices. Pharmaceutical is further divided into small molecule and biologic. By application, it is categorized into cardiovascular, oncology, dermatology, musculoskeletal, wound healing, ophthalmology, neurology, and others. Geographically, it is analyzed across four regions, i.e., North America, Europe, Asia-Pacific, and LAMEA.

KEY MARKET BENEFITS FOR STAKEHOLDERS

  • This report offers a detailed quantitative analysis of the market trends from 2016 to 2023 to identify the prevailing opportunities.
  • The market estimations provided in this report are based on a comprehensive analysis of the key developments in the industry.
  • An in-depth analysis based on geography facilitates the study of the regional market to assist in strategic business planning.
  • The development strategies adopted by the key manufacturers are enlisted in the report to understand the competitive scenario of the market.

KEY MARKET SEGMENTS

By Product Type

  • Cell Therapy
  • Gene Therapy
  • Tissue Engineering
  • Small Molecule & Biologic

By Material

  • Synthetic Material
  • Biodegradable Synthetic Polymer
  • Scaffold
  • Artificial Vascular Graft Material
  • Hydrogel Material
  • Biologically Derived Material
  • Collagen
  • Xenogeneic Material
  • Genetically Engineered Material
  • Deoxyribonucleic Acid Transfection Vectors
  • Genetically Manipulated Cell
  • Three-Dimensional Polymer Technology
  • Transgenic
  • Fibroblast
  • Neural Stem Cell
  • Gene-Activated Matrices
  • Pharmaceuticals
  • Small Molecule
  • Biologic

By Application

  • Cardiovascular
  • Oncology
  • Dermatology
  • Musculoskeletal
  • Wound Healing
  • Ophthalmology
  • Neurology
  • Others

By Region

  • North America
  • U.S.
  • Canada
  • Mexico
  • Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Russia
  • Netherlands
  • Sweden
  • Rest of Europe
  • Asia-Pacific
  • Japan
  • China
  • Australia
  • India
  • Singapore
  • Rest of Asia-Pacific
  • LAMEA
  • Brazil
  • Turkey
  • Saudi Arabia
  • South Africa
  • Rest of LAMEA

KEY PLAYERS PROFILED

  • Stryker Corporation
  • Zimmer Biomet Holdings, Inc.
  • Medtronic Plc.
  • Athersys, Inc.
  • U.S. Stem Cell, Inc. (Bioheart, Inc.)
  • Organogenesis, Inc. (Advanced Biohealing)
  • Integra Lifesciences Holdings Corporation
  • Acelity Holdings, Inc.
  • Isto Biologics (Isto Biologics Medical Systems, Inc.)
  • CryoLife, Inc.

The other players of the Regenerative Medicine market include (companies not profiled in the report):

  • Shimadzu Recursion Pharmaceuticals, Inc.
  • Baxter International, Inc.
  • DePuy Synthes
  • Siemens Healthineers
  • General Electric (GE) Company
  • Koninklijke Philips N.V.
  • Cloudmedx, Inc.
  • Bay Labs, Inc.

Table of Contents

CHAPTER 1: INTRODUCTION

  • 1.1. Report Description
  • 1.2. Key Benefits For Stakeholders
  • 1.3. Key Market Segments
  • 1.4. Research Methodology
    • 1.4.1. Secondary research
    • 1.4.2. Primary research
    • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

  • 3.1. Market Definition And Scope
  • 3.2. Key Findings
    • 3.2.1. Top investment pockets
    • 3.2.2. Top winning strategies
  • 3.3. Porters Five Forces Analysis
  • 3.4. Market Dynamics
    • 3.4.1. Drivers
      • 3.4.1.1. High adoption of stem cell technology
      • 3.4.1.2. Emerging application of nanotechnology
      • 3.4.1.3. Increasing prevalence of chronic diseases and trauma emergencies
      • 3.4.1.4. Advancements in medical equipment technologies
    • 3.4.2. Restraints
      • 3.4.2.1. Ethical hurdles
      • 3.4.2.2. Costly treatment associated with regenerative medicine
    • 3.4.3. Opportunities
      • 3.4.3.1. Lucrative opportunities of novel stem cell technologies
      • 3.4.3.2. Increasing potential in emerging economies
      • 3.4.3.3. Growing need of regenerative medicine in organ transplantation

CHAPTER 4: REGENERATIVE MEDICINE MARKET, BY PRODUCT TYPE

  • 4.1. Overview
    • 4.1.1. Market size and forecast
  • 4.2. Cell Therapy
    • 4.2.1. Key market trends
    • 4.2.2. Key growth factors and growth opportunities
    • 4.2.3. Market size and forecast
  • 4.3. Gene Therapy
    • 4.3.1. Key market trends
    • 4.3.2. Key growth factors and growth opportunities
    • 4.3.3. Market size and forecast
  • 4.4. Tissue Engineering
    • 4.4.1. Key market trends
    • 4.4.2. Key growth factors and opportunities
    • 4.4.3. Market size and forecast
  • 4.5. Small Molecules And Biologics
    • 4.5.1. Key market trends
    • 4.5.2. Key growth factors and opportunities
    • 4.5.3. Market size and forecast

CHAPTER 5: REGENERATIVE MEDICINE MARKET, BY MATERIAL

  • 5.1. Overview
    • 5.1.1. Market size and forecast
  • 5.2. Synthetic Materials
    • 5.2.1. Market size and forecast, by region
    • 5.2.2. Market size and forecast, by type
    • 5.2.3. Biodegradable synthetic polymers
      • 5.2.3.1. Market size and forecast
    • 5.2.4. Scaffold
      • 5.2.4.1. Market size and forecast
    • 5.2.5. Artificial vascular graft materials
      • 5.2.5.1. Market size and forecast
    • 5.2.6. Hydrogel material
      • 5.2.6.1. Market size and forecast
  • 5.3. Biologically Derived Materials
    • 5.3.1. Market size and forecast, by region
    • 5.3.2. Market size and forecast, by type
    • 5.3.3. Collagen
      • 5.3.3.1. Market size and forecast
    • 5.3.4. Xenogeneic material
      • 5.3.4.1. Market size and forecast
  • 5.4. Genetically Engineered Materials
    • 5.4.1. Market size and forecast, by region
    • 5.4.2. Market size and forecast, by type
    • 5.4.3. Deoxyribonucleic acid transfection vectors
      • 5.4.3.1. Market size and forecast
    • 5.4.4. Genetically manipulated cells
      • 5.4.4.1. Market size and forecast
    • 5.4.5. Three-dimensional polymer technology
      • 5.4.5.1. Market size and forecast
    • 5.4.6. Transgenics
      • 5.4.6.1. Market size and forecast
    • 5.4.7. Fibroblasts
      • 5.4.7.1. Market size and forecast
    • 5.4.8. Neural stem cells
      • 5.4.8.1. Market size and forecast
    • 5.4.9. Gene-activated matrices
      • 5.4.9.1. Market size and forecast
  • 5.5. Pharmaceuticals
    • 5.5.1. Market size and forecast, by region
    • 5.5.2. Market size and forecast, by type
    • 5.5.3. Small molecules
      • 5.5.3.1. Market size and forecast
    • 5.5.4. Biologics
      • 5.5.4.1. Market size and forecast

CHAPTER 6: REGENERATIVE MEDICINE MARKET, BY APPLICATION

  • 6.1. Overview
    • 6.1.1. Market size and forecast
  • 6.2. Cardiovascular
    • 6.2.1. Market size and forecast
  • 6.3. Oncology
    • 6.3.1. Market size and forecast
  • 6.4. Dermatology
    • 6.4.1. Market size and forecast
  • 6.5. Musculoskeletal
    • 6.5.1. Market size and forecast
  • 6.6. Wound Healing
    • 6.6.1. Market size and forecast
  • 6.7. Ophthalmology
    • 6.7.1. Market size and forecast
  • 6.8. Neurology
    • 6.8.1. Market size and forecast
  • 6.9. Others
    • 6.9.1. Market size and forecast

CHAPTER 7: REGENERATIVE MEDICINE MARKET, BY REGION

  • 7.1. Overview
    • 7.1.1. Market size and forecast
  • 7.2. North America
    • 7.2.1. Key market trends
    • 7.2.2. Key growth factors and opportunities
    • 7.2.3. Market size and forecast, by product type
    • 7.2.4. Market size and forecast, by material
    • 7.2.5. Market size and forecast, by application
    • 7.2.6. Market size and forecast, by country
      • 7.2.6.1. U.S. market size and forecast
      • 7.2.6.2. Canada market size and forecast
      • 7.2.6.3. Mexico market size and forecast
  • 7.3. Europe
    • 7.3.1. Key market trends
    • 7.3.2. Key growth factors and opportunities
    • 7.3.3. Market size and forecast, by product type
    • 7.3.4. Market size and forecast, by material
    • 7.3.5. Market size and forecast, by application
    • 7.3.6. Market size and forecast, by country
      • 7.3.6.1. Germany market size and forecast
      • 7.3.6.2. France market size and forecast
      • 7.3.6.3. UK market size and forecast
      • 7.3.6.4. Italy market size and forecast
      • 7.3.6.5. Spain market size and forecast
      • 7.3.6.6. Russia market size and forecast
      • 7.3.6.7. Rest of Europe market size and forecast
  • 7.4. Asia-Pacific
    • 7.4.1. Key market trends
    • 7.4.2. Key growth factors and opportunities
    • 7.4.3. Market size and forecast, by product type
    • 7.4.4. Market size and forecast, by material
    • 7.4.5. Market size and forecast, by application
    • 7.4.6. Market size and forecast, by country
      • 7.4.6.1. Japan market size and forecast
      • 7.4.6.2. China market size and forecast
      • 7.4.6.3. Australia market size and forecast
      • 7.4.6.4. India market size and forecast
      • 7.4.6.5. South Korea market size and forecast
      • 7.4.6.6. Taiwan market size and forecast
      • 7.4.6.7. Rest of Asia-Pacific market size and forecast
  • 7.5. Lamea
    • 7.5.1. Key market trends
    • 7.5.2. Key growth factors and opportunities
    • 7.5.3. Market size and forecast, by product type
    • 7.5.4. Market size and forecast, by material
    • 7.5.5. Market size and forecast, by application
    • 7.5.6. Market size and forecast, by country
      • 7.5.6.1. Brazil market size and forecast
      • 7.5.6.2. Turkey market size and forecast
      • 7.5.6.3. Venezuela market size and forecast
      • 7.5.6.4. Saudi Arabia market size and forecast
      • 7.5.6.5. South Africa market size and forecast
      • 7.5.6.6. Rest of LAMEA market size and forecast

CHAPTER 8: COMPANY PROFILES

  • 8.1. Acelity Holdings, Inc. (Lifecell Corporation)
    • 8.1.1. Company overview
    • 8.1.2. Company snapshot
    • 8.1.3. Operating business segments
    • 8.1.4. Key strategic moves and developments
  • 8.2. Athersys, Inc.
    • 8.2.1. Company overview
    • 8.2.2. Company snapshot
    • 8.2.3. Operating business segments
    • 8.2.4. Business performance
    • 8.2.5. Key strategic moves and developments
  • 8.3. Cryolife, Inc.
    • 8.3.1. Company overview
    • 8.3.2. Company snapshot
    • 8.3.3. Operating business segments
    • 8.3.4. Business performance
  • 8.4. Integra Lifesciences Corporation
    • 8.4.1. Company overview
    • 8.4.2. Company snapshot
    • 8.4.3. Operating business segments
    • 8.4.4. Business performance
    • 8.4.5. Key strategic moves and developments
  • 8.5. Isto Biologics (Isto Biologics Medical Systems, Inc.)
    • 8.5.1. Company overview
    • 8.5.2. Company snapshot
    • 8.5.3. Key strategic moves and developments
  • 8.6. Medtronic Plc
    • 8.6.1. Company overview
    • 8.6.2. Company snapshot
    • 8.6.3. Operating business segments
    • 8.6.4. Business performance
  • 8.7. Organogenesis Inc.
    • 8.7.1. Company overview
    • 8.7.2. Company snapshot
    • 8.7.3. Key strategic moves and developments
  • 8.8. Stryker Corporation
    • 8.8.1. Company overview
    • 8.8.2. Company snapshot
    • 8.8.3. Operating business segments
    • 8.8.4. Business performance
    • 8.8.5. Key strategic moves and developments
  • 8.9. U.S. Stem Cell, Inc. (Bioheart, Inc.)
    • 8.9.1. Company overview
    • 8.9.2. Company snapshot
    • 8.9.3. Operating business segments
    • 8.9.4. Business performance
    • 8.9.5. Key strategic moves and developments
  • 8.10. Zimmer Biomet Holdings, Inc.
    • 8.10.1. Company overview
    • 8.10.2. Company snapshot
    • 8.10.3. Operating business segments
    • 8.10.4. Business performance
    • 8.10.5. Key strategic moves and developments

List of Tables

  • TABLE 01. UNINTENTIONAL INJURIES FACTS (2013)
  • TABLE 02. GLOBAL REGENERATIVE MEDICINE MARKET, BY PRODUCT TYPE, 2016-2023 ($MILLION)
  • TABLE 03. REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY REGION, 2016-2023 ($MILLION)
  • TABLE 04. REGENERATIVE MEDICINE MARKET FOR GENE THERAPY, BY REGION, 2016-2023 ($MILLION)
  • TABLE 05. REGENERATIVE MEDICINE MARKET FOR TISSUE ENGINEERING, BY REGION, 2016-2023 ($MILLION)
  • TABLE 06. REGENERATIVE MEDICINE MARKET FOR SMALL MOLECULES & BIOLOGICS, BY REGION, 2016-2023 ($MILLION)
  • TABLE 07. GLOBAL REGENERATIVE MEDICINE MARKET, BY MATERIAL, 2016-2023 ($MILLION)
  • TABLE 08. REGENERATIVE MEDICINE MARKET FOR SYNTHETIC MATERIAL, BY REGION, 2016-2023 ($MILLION)
  • TABLE 09. REGENERATIVE MEDICINE MARKET FOR SYNTHETIC MATERIAL, BY TYPE, 2016-2023 ($MILLION)
  • TABLE 10. CLASSIFICATION OF BIODEGRADABLE POLYMERS
  • TABLE 11. REGENERATIVE MEDICINE MARKET FOR BIODEGRADABLE SYNTHETIC POLYMER, BY REGION, 2016-2023 ($MILLION)
  • TABLE 12. CLASSIFICATION OF BIODEGRADABLE POLYMERS
  • TABLE 13. REGENERATIVE MEDICINE MARKET FOR SCAFFOLD, BY REGION, 2016-2023 ($MILLION)
  • TABLE 14. REGENERATIVE MEDICINE MARKET FOR ARTIFICIAL VASCULAR GRAFT MATERIALS, BY REGION, 2016-2023 ($MILLION)
  • TABLE 15. REGENERATIVE MEDICINE MARKET FOR HYDROGEL MATERIAL, BY REGION, 2016-2023 ($MILLION)
  • TABLE 16. REGENERATIVE MEDICINE MARKET FOR BIOLOGICALLY DERIVED MATERIALS, BY REGION, 2016-2023 ($MILLION)
  • TABLE 17. REGENERATIVE MEDICINE MARKET FOR BIOLOGICALLY DERIVED MATERIALS, BY TYPE, 2016-2023 ($MILLION)
  • TABLE 18. REGENERATIVE MEDICINE MARKET FOR COLLAGEN MATERIAL, BY REGION, 2016-2023 ($MILLION)
  • TABLE 19. REGENERATIVE MEDICINE MARKET FOR XENOGENEIC MATERIAL, BY REGION, 2016-2023 ($MILLION)
  • TABLE 20. REGENERATIVE MEDICINE MARKET FOR GENETICALLY ENGINEERED MATERIALS, BY REGION, 2016-2023 ($MILLION)
  • TABLE 21. REGENERATIVE MEDICINE MARKET FOR GENETICALLY ENGINEERED MATERIALS, BY TYPE, 2016-2023 ($MILLION)
  • TABLE 22. REGENERATIVE MEDICINE MARKET FOR DEOXYRIBONUCLEIC ACID TRANSFECTION VECTORS, BY REGION, 2016-2023 ($MILLION)
  • TABLE 23. REGENERATIVE MEDICINE MARKET FOR GENETICALLY MANIPULATED CELLS, BY REGION, 2016-2023 ($MILLION)
  • TABLE 24. REGENERATIVE MEDICINE MARKET FOR THREE-DIMENSIONAL POLYMER TECHNOLOGY, BY REGION, 2016-2023 ($MILLION)
  • TABLE 25. REGENERATIVE MEDICINE MARKET FOR TRANSGENICS, BY REGION, 2016-2023 ($MILLION)
  • TABLE 26. REGENERATIVE MEDICINE MARKET FOR FIBROBLASTS, BY REGION, 2016-2023 ($MILLION)
  • TABLE 27. REGENERATIVE MEDICINE MARKET FOR NEURAL STEM CELLS, BY REGION, 2016-2023 ($MILLION)
  • TABLE 28. REGENERATIVE MEDICINE MARKET FOR GENE-ACTIVATED MATRICES, BY REGION, 2016-2023 ($MILLION)
  • TABLE 29. REGENERATIVE MEDICINE MARKET FOR PHARMACEUTICALS, BY REGION, 2016-2023 ($MILLION)
  • TABLE 30. REGENERATIVE MEDICINE MARKET FOR PHARMACEUTICALS, BY TYPE, 2016-2023 ($MILLION)
  • TABLE 31. REGENERATIVE MEDICINE MARKET FOR SMALL MOLECULES, BY REGION, 2016-2023 ($MILLION)
  • TABLE 32. REGENERATIVE MEDICINE MARKET FOR BIOLOGICS, BY REGION, 2016-2023 ($MILLION)
  • TABLE 33. GLOBAL REGENERATIVE MEDICINE MARKET, BY APPLICATION, 2016-2023 ($MILLION)
  • TABLE 34. REGENERATIVE MEDICINE MARKET FOR CARDIOVASCULAR, BY REGION, 2016-2023 ($MILLION)
  • TABLE 35. REGENERATIVE MEDICINE MARKET FOR ONCOLOGY, BY REGION, 2016-2023 ($MILLION)
  • TABLE 36. STATISTICS FOR SKIN DAMAGE MEDICAL CONDITIONS IN THE U.S. AND WORLDWIDE, 2011
  • TABLE 37. LIST OF ACELLULAR SKIN TISSUE-ENGINEERED PRODUCTS IN THE MARKET
  • TABLE 38. LIST OF CELLULAR SKIN TISSUE-ENGINEERED PRODUCTS IN THE MARKET
  • TABLE 39. REGENERATIVE MEDICINE MARKET FOR DERMATOLOGY, BY REGION, 2016-2023 ($MILLION)
  • TABLE 40. STATISTICS FOR BONE DAMAGE AND RELATED DISEASES, 2011
  • TABLE 41. STATISTICS FOR CARTILAGE DAMAGE WORLDWIDE
  • TABLE 42. REGENERATIVE MEDICINE MARKET FOR MUSCULOSKELETAL, BY REGION, 2016-2023 ($MILLION)
  • TABLE 43. REGENERATIVE MEDICINE MARKET FOR WOUND HEALING, BY REGION, 2016-2023 ($MILLION)
  • TABLE 44. REGENERATIVE MEDICINE MARKET FOR OPHTHALMOLOGY, BY REGION, 2016-2023 ($MILLION)
  • TABLE 45. REGENERATIVE MEDICINE MARKET FOR NEUROLOGY, BY REGION, 2016-2023 ($MILLION)
  • TABLE 46. REGENERATIVE MEDICINE MARKET FOR OTHER APPLICATION, BY REGION, 2016-2023 ($MILLION)
  • TABLE 47. REGENERATIVE MEDICINE MARKET, BY REGION, 2016-2023 ($MILLION)
  • TABLE 48. NORTH AMERICA REGENERATIVE MEDICINE MARKET, BY PRODUCT TYPE, 2016-2023 ($MILLION)
  • TABLE 49. NORTH AMERICA REGENERATIVE MEDICINE MARKET, BY MATERIAL, 2016-2023 ($MILLION)
  • TABLE 50. NORTH AMERICA REGENERATIVE MEDICINE MARKET FOR SYNTHETIC MATERIAL, 2016-2023 ($MILLION)
  • TABLE 51. NORTH AMERICA REGENERATIVE MEDICINE MARKET FOR BIOLOGICALLY DERIVED MATERIAL, 2016-2023 ($MILLION)
  • TABLE 52. NORTH AMERICA REGENERATIVE MEDICINE MARKET FOR GENETICALLY ENGINEERED MATERIAL, 2016-2023 ($MILLION)
  • TABLE 53. NORTH AMERICA REGENERATIVE MEDICINE MARKET FOR PHARMACEUTICALS, 2016-2023 ($MILLION)
  • TABLE 54. NORTH AMERICA REGENERATIVE MEDICINE MARKET, BY APPLICATION, 2016-2023 ($MILLION)
  • TABLE 55. NORTH AMERICA REGENERATIVE MEDICINE MARKET, BY COUNTRY, 2016-2023 ($MILLION)
  • TABLE 56. EUROPE REGENERATIVE MEDICINE MARKET, BY PRODUCT TYPE, 2016-2023 ($MILLION)
  • TABLE 57. EUROPE REGENERATIVE MEDICINE MARKET, BY MATERIAL, 2016-2023 ($MILLION)
  • TABLE 58. EUROPE REGENERATIVE MEDICINE MARKET FOR SYNTHETIC MATERIAL, 2016-2023 ($MILLION)
  • TABLE 59. EUROPE REGENERATIVE MEDICINE MARKET FOR BIOLOGICALLY DERIVED MATERIAL, 2016-2023 ($MILLION)
  • TABLE 60. EUROPE REGENERATIVE MEDICINE MARKET FOR GENETICALLY ENGINEERED MATERIAL, 2016-2023 ($MILLION)
  • TABLE 61. EUROPE REGENERATIVE MEDICINE MARKET FOR PHARMACEUTICALS, 2016-2023 ($MILLION)
  • TABLE 62. EUROPE REGENERATIVE MEDICINE MARKET, BY APPLICATION, 2016-2023 ($MILLION)
  • TABLE 63. EUROPE REGENERATIVE MEDICINE MARKET, BY COUNTRY, 2016-2023 ($MILLION)
  • TABLE 64. ASIA-PACIFIC REGENERATIVE MEDICINE MARKET, BY PRODUCT TYPE, 2016-2023 ($MILLION)
  • TABLE 65. ASIA-PACIFIC REGENERATIVE MEDICINE MARKET, BY MATERIAL, 2016-2023 ($MILLION)
  • TABLE 66. ASIA-PACIFIC REGENERATIVE MEDICINE MARKET FOR SYNTHETIC MATERIAL, 2016-2023 ($MILLION)
  • TABLE 67. ASIA-PACIFIC REGENERATIVE MEDICINE MARKET FOR BIOLOGICALLY DERIVED MATERIAL, 2016-2023 ($MILLION)
  • TABLE 68. ASIA-PACIFIC REGENERATIVE MEDICINE MARKET FOR GENETICALLY ENGINEERED MATERIAL, 2016-2023 ($MILLION)
  • TABLE 69. ASIA-PACIFIC REGENERATIVE MEDICINE MARKET FOR PHARMACEUTICALS, 2016-2023 ($MILLION)
  • TABLE 70. ASIA-PACIFIC REGENERATIVE MEDICINE MARKET, BY APPLICATION, 2016-2023 ($MILLION)
  • TABLE 71. ASIA-PACIFIC REGENERATIVE MEDICINE MARKET, BY COUNTRY, 2016-2023 ($MILLION)
  • TABLE 72. LAMEA REGENERATIVE MEDICINE MARKET, BY PRODUCT TYPE, 2016-2023 ($MILLION)
  • TABLE 73. LAMEA REGENERATIVE MEDICINE MARKET, BY MATERIAL, 2016-2023 ($MILLION)
  • TABLE 74. LAMEA REGENERATIVE MEDICINE MARKET FOR SYNTHETIC MATERIAL, 2016-2023 ($MILLION)
  • TABLE 75. LAMEA REGENERATIVE MEDICINE MARKET FOR BIOLOGICALLY DERIVED MATERIAL, 2016-2023 ($MILLION)
  • TABLE 76. LAMEA REGENERATIVE MEDICINE MARKET FOR GENETICALLY ENGINEERED MATERIAL, 2016-2023 ($MILLION)
  • TABLE 77. LAMEA REGENERATIVE MEDICINE MARKET FOR PHARMACEUTICALS, 2016-2023 ($MILLION)
  • TABLE 78. LAMEA REGENERATIVE MEDICINE MARKET, BY APPLICATION, 2016-2023 ($MILLION)
  • TABLE 79. LAMEA REGENERATIVE MEDICINE MARKET, BY COUNTRY, 2016-2023 ($MILLION)
  • TABLE 80. ACELITY: COMPANY SNAPSHOT
  • TABLE 81. ACELITY: THREE TECHNOLOGIES
  • TABLE 82. ATHERSYS: COMPANY SNAPSHOT
  • TABLE 83. ATHERSYS: OPERATING SEGMENTS
  • TABLE 84. CRYOLIFE: COMPANY SNAPSHOT
  • TABLE 85. CRYOLIFE: PRODUCT CATEGORIES
  • TABLE 86. INTEGRA LIFESCIENCES: COMPANY SNAPSHOT
  • TABLE 87. INTEGRA LIFESCIENCES: OPERATING SEGMENTS
  • TABLE 88. ISTO BIOLOGICS: COMPANY SNAPSHOT
  • TABLE 89. MEDTRONIC: COMPANY SNAPSHOT
  • TABLE 90. MEDTRONIC: PRODUCT CATEGORIES
  • TABLE 91. ORGANOGENESIS: COMPANY SNAPSHOT
  • TABLE 92. STRYKER: COMPANY SNAPSHOT
  • TABLE 93. STRYKER: OPERATING SEGMENTS
  • TABLE 94. US STEM CELL: COMPANY SNAPSHOT
  • TABLE 95. ZIMMER BIOMET: COMPANY SNAPSHOT
  • TABLE 96. ZIMMER BIOMET: OPERATING SEGMENTS

List of Figures

  • FIGURE 01. GLOBAL REGENERATIVE MEDICINE MARKET SEGMENTATION
  • FIGURE 02. TOP INVESTMENT POCKETS
  • FIGURE 03. TOP WINNING STRATEGIES, BY YEAR, 2016-2018*
  • FIGURE 04. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2016-2018* (%)
  • FIGURE 05. TOP WINNING STRATEGIES, BY COMPANY, 2016-2018*
  • FIGURE 06. LOW BARGAINING POWER OF BUYERS
  • FIGURE 07. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 08. HIGH THREAT OF NEW ENTRANTS
  • FIGURE 09. LOW THREAT OF SUBSTITUTION
  • FIGURE 10. HIGH COMPETITIVE RIVALRY
  • FIGURE 11. U.S. REGENERATIVE MEDICINE MARKET, 2016-2023 ($MILLION)
  • FIGURE 12. CANADA REGENERATIVE MEDICINE MARKET, 2016-2023 ($MILLION)
  • FIGURE 13. MEXICO REGENERATIVE MEDICINE MARKET, 2016-2023 ($MILLION)
  • FIGURE 14. GERMANY REGENERATIVE MEDICINE MARKET, 2016-2023 ($MILLION)
  • FIGURE 15. FRANCE REGENERATIVE MEDICINE MARKET, 2016-2023 ($MILLION)
  • FIGURE 16. UK REGENERATIVE MEDICINE MARKET, 2016-2023 ($MILLION)
  • FIGURE 17. ITALY REGENERATIVE MEDICINE MARKET, 2016-2023 ($MILLION)
  • FIGURE 18. SPAIN REGENERATIVE MEDICINE MARKET, 2016-2023 ($MILLION)
  • FIGURE 19. RUSSIA REGENERATIVE MEDICINE MARKET, 2016-2023 ($MILLION)
  • FIGURE 20. REST OF EUROPE REGENERATIVE MEDICINE MARKET, 2016-2023 ($MILLION)
  • FIGURE 21. JAPAN REGENERATIVE MEDICINE MARKET, 2016-2023 ($MILLION)
  • FIGURE 22. CHINA REGENERATIVE MEDICINE MARKET, 2016-2023 ($MILLION)
  • FIGURE 23. AUSTRALIA REGENERATIVE MEDICINE MARKET, 2016-2023 ($MILLION)
  • FIGURE 24. INDIA REGENERATIVE MEDICINE MARKET, 2016-2023 ($MILLION)
  • FIGURE 25. SOUTH KOREA REGENERATIVE MEDICINE MARKET, 2016-2023 ($MILLION)
  • FIGURE 26. TAIWAN REGENERATIVE MEDICINE MARKET, 2016-2023 ($MILLION)
  • FIGURE 27. REST OF ASIA-PACIFIC REGENERATIVE MEDICINE MARKET, 2016-2023 ($MILLION)
  • FIGURE 28. BRAZIL REGENERATIVE MEDICINE MARKET, 2016-2023 ($MILLION)
  • FIGURE 29. TURKEY REGENERATIVE MEDICINE MARKET, 2016-2023 ($MILLION)
  • FIGURE 30. VENEZUELA REGENERATIVE MEDICINE MARKET, 2016-2023 ($MILLION)
  • FIGURE 31. SAUDI ARABIA REGENERATIVE MEDICINE MARKET, 2016-2023 ($MILLION)
  • FIGURE 32. SOUTH AFRICA REGENERATIVE MEDICINE MARKET, 2016-2023 ($MILLION)
  • FIGURE 33. REST OF LAMEA REGENERATIVE MEDICINE MARKET, 2016-2023 ($MILLION)
  • FIGURE 34. ATHERSYS: REVENUE, 2015-2017 ($MILLION)
  • FIGURE 35. ATHERSYS: REVENUE SHARE BY SEGMENT, 2016 (%)
  • FIGURE 36. ATHERSYS: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
  • FIGURE 37. CRYOLIFE: REVENUE, 2015-2017 ($MILLION)
  • FIGURE 38. CRYOLIFE: REVENUE SHARE BY SEGMENT, 2017 (%)
  • FIGURE 39. CRYOLIFE: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
  • FIGURE 40. INTEGRA LIFESCIENCES: REVENUE, 2015-2017 ($MILLION)
  • FIGURE 41. INTEGRA LIFESCIENCES: REVENUE SHARE BY SEGMENT, 2017 (%)
  • FIGURE 42. INTEGRA LIFESCIENCES: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
  • FIGURE 43. MEDTRONIC: NET SALES, 2015-2017 ($MILLION)
  • FIGURE 44. MEDTRONIC: REVENUE SHARE PER SEGMENT 2017 (%)
  • FIGURE 45. MEDTRONIC: REVENUE SHARE BY GEOGRAPHY 2017 (%)
  • FIGURE 46. STRYKER: REVENUE, 2015-2017 ($MILLION)
  • FIGURE 47. STRYKER: REVENUE SHARE BY SEGMENT, 2017 (%)
  • FIGURE 48. STRYKER LIFESCIENCES: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
  • FIGURE 49. US STEM CELL: REVENUE, 2015-2017 ($MILLION)
  • FIGURE 50. US STEM CELL: REVENUE SHARE BY SEGMENT, 2017 (%)
  • FIGURE 51. US STEM CELL: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
  • FIGURE 52. ZIMMER BIOMET: REVENUE, 2015-2017 ($MILLION)
  • FIGURE 53. ZIMMER BIOMET: REVENUE SHARE BY SEGMENT, 2017 (%)
  • FIGURE 54. ZIMMER BIOMET: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
Back to Top